Skip to content

Author

M. Vaduganathan

9 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 11858: Combination Therapy with Finerenone and Empagliflozin by Baseline Risk of Liver Fibrosis in the CONFIDENCE Trial

Background: The liver is an important organ in cardio-kidney-metabolic (CKM) disease because of its essential roles in glucose homeostasis, cholesterol synthesis, and drug metabolism. We evaluated whether baseline liver fibrosis risk, estimated using the Fibrosis-4 (FIB-4) index, influenced treatment responses to es...

R. Helseth, J. Green, J. McGill et al. · 0 citations
Open access Jul 2026

Prevalence and clinical correlates of metabolic dysfunction-associated steatotic liver disease in heart failure

Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...

N. Chew, Chandramouli Chanchal, W. Tay et al. · 0 citations
Open access Aug 2026

Serial high-sensitivity troponin-T and risk of heart failure in individuals with suspected acute coronary syndrome.

AIMS To investigate the association between serial high-sensitivity cardiac troponin-T (hs-TnT) concentrations and subsequent heart failure in individuals presenting with suspected acute coronary syndrome (ACS). METHODS AND RESULTS Utilizing Danish nationwide registries, we identified individuals without known heart...

Philip Ahle Erichsen, Majid Afzal, Christina Byrne et al. · 1 citation
Oct 2026

Sex Differences in the Prevalence, Medical Therapy, and Outcomes in Heart Failure With Improved Ejection Fraction.

BACKGROUND Heart failure with improved ejection fraction (HFimpEF) is a rapidly growing clinical entity. There is little understanding of how sex relates to the epidemiology, predictors, and trajectory of HFimpEF. OBJECTIVES The authors aimed to describe sex-based differences in the epidemiology, guideline-directed m...

Yi-Lin Liang, Lochan M. Shah, R. Parikh et al. · 1 citation
Open access Aug 2026

Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

BACKGROUND AND AIMS N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended to guide echocardiography referral in community-based patients with suspected heart failure (HF), but diagnostic performance is influenced by individual characteristics including age, ethnicity, kidney function, cardiac rhythm, and...

K. Docherty, B. Heywood, L. Anderson et al. · 0 citations
Open access Aug 2026

The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.

BACKGROUND Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) face high but modifiable risks of incident heart failure (HF). We aimed to ascertain whether the HFpEF-ABA score, a simple 3-variable tool to facilitate timely diagnosis of HFpEF, is associated with adverse cardiovascular (CV) outcomes in p...

R. Inciardi, J. Ostrominski, B. Claggett et al. · 0 citations
Oct 2026

Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement.

Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular-kidney-metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently...

R. Inciardi, A. Abdin, M. Abdelhamid et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.